1. Essential Concepts in Harnessing the Immune System in Head and Neck Cancer

3. 1899: Coley’s Toxin

4. 2016: PD-1 Inhibition

5. 2016: PD-1 Inhibition

6. Overview

7. Tumor Immunology Cycle

8. The Yin and Yang of Immune Escape

9. Cancer Is Highly Immunosuppressive

10. T Cells Killing a Tumor Cell

11. Inflamed Phenotype in HNC TILs

12. Inflamed/Mesenchymal Intrinsic HNC Subtype

13. Clinical Activity

14. Recurrent and/or Metastatic HNC

15. Some of the PD-1/PD-L1 and CTLA-4 Targeting Agents in Development

16. KEYNOTE-055: Phase 2 Trial of Pembrolizumab After Progression

17. KEYNOTE-055: ORR

18. EXTREME vs Immunotherapy The Tail at the End of the Curve

19. Tumor Shrinkage

20. Case Study

21. Case Study (cont)

23. CheckMate 141: Phase 3 Trial of Nivolumab After Progression

24. CheckMate 141: OS

25. How Do We Select Patients? Biomarkers

26. PD-L1 Expression in Head and Neck Cancer

27. CheckMate 141: OS by Tumor PD-L1 Expression

28. Association of IFN-γ Signature and PFS

29. PFS and OS by IFN-γ 6-Gene Signature Score

30. CheckMate 141: OS by p16 Status

31. Adverse Effect Management

32. KEYNOTE-055: TRAEs With Pembrolizumab

33. Overview of irAEs

34. The Future: Immunotherapy Combinations

35. Combination Therapy

36. Immunotherapy in the First-Line Setting

37. Immunotherapy in the First-Line Setting (cont)

38. Immunotherapy in the First-Line Setting (cont)

39. Making Tumors Inflamed: T-VEC

40. Changing the Immunosuppressive ME: IDO

41. Ongoing and Future Clinical Concepts

42. Take-Home Messages

43. Abbreviations

44. Abbreviations (cont)

45. Abbreviations (cont)

46. Abbreviations (cont)